Recent developments in drug therapy for cushing's disease

Drugs

Volumn 73, Issue 9, 2013, Pages 907-918

  Van Der Pas, Rob ^a   De Herder, Wouter W ^a   Hofland, Leo J ^a   Feelders, Richard A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; ETOMIDATE; FLUCONAZOLE; GEFITINIB; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ANTAGONIST; KETOCONAZOLE; LCI 699; METYRAPONE; MIFEPRISTONE; MINERALOCORTICOID; MITOTANE; OCTREOTIDE; PASIREOTIDE; RETINOIC ACID; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; BONE MARROW SUPPRESSION; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN RELEASE; CUSHING DISEASE; CUSHING SYNDROME; DIZZINESS; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM HYPERPLASIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPOGONADISM; HYPOKALEMIA; HYPOPITUITARISM; HYPOTENSION; INSULIN RELEASE; LIFE EXPECTANCY; LIVER TOXICITY; LOW DRUG DOSE; NEUROLOGIC DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; REVIEW; STEROIDOGENESIS; TREATMENT RESPONSE; TUMOR VOLUME;

ACTH-SECRETING PITUITARY ADENOMA; ADRENAL GLANDS; ANIMALS; HUMANS; IMIDAZOLES; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PYRIDINES;

EID: 84879478283     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0067-6     Document Type: Review

References (98)

1. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96(3):632-42.
2. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab. 2007;92(3):976-81. (Pubitemid 46465672)
3. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117-23. (Pubitemid 32111743)
4. Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. Lancet. 2001;357(9258):783-91. (Pubitemid 32217692)
5. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367(9522):1605-17. (Pubitemid 43674231)
6. Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):65-70.
7. Tiemensma J, Biermasz NR, Middelkoop HA, van der Mast RC, Romijn JA, Pereira AM. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease. J Clin Endocrinol Metab. 2010;95(10):E129-41.
8. Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary. 2003;6(2):81-7. (Pubitemid 37536859)
9. Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, et al. Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol. 2008;158(5):623-30. (Pubitemid 351639599)
10. Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev. 2011;7(5):279-89.
11. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf). 2005;63(5):549-59. (Pubitemid 41626751)
12. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454-62. (Pubitemid 352008503)
13. Mullan KR, Atkinson AB. Endocrine clinical update: where are we in the therapeutic management of pituitary-dependent hypercortisolism? Clin Endocrinol (Oxf). 2008;68(3):327-37. (Pubitemid 351257845)
14. Rees DA, Hanna FW, Davies JS, Mills RG, Vafidis J, Scanlon MF. Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf). 2002;56(4):541-51. (Pubitemid 34429630)
15. Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 2006;91(1):7-13. (Pubitemid 43069107)
16. Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH. Early repeat surgery for persistent Cushing's disease. J Neurosurg. 1994;80(1):37-45. (Pubitemid 24020703)
17. Vance ML. Pituitary radiotherapy. Endocrinology and metabolism clinics of North America. 2005;34(2):479-87, xi. (Pubitemid 40602733)
18. Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab. 2008;93(2):393-9. (Pubitemid 351246676)
19. Devin JK, Allen GS, Cmelak AJ, Duggan DM, Blevins LS. The efficacy of linear accelerator radiosurgery in the management of patients with Cushing's disease. Stereotact Funct Neurosurg. 2004;82(5-6):254-62.
20. Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997;336(3):172-7. (Pubitemid 27034962)
21. Morris D, Grossman A. The medical management of Cushing's syndrome. Ann N Y Acad Sci. 2002;970:119-33. (Pubitemid 35286089)
22. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311-26.
23. de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab. 2009;94(4):1118-24.
24. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89(5):2452-62. (Pubitemid 38619889)
25. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. Eur J Endocrinol. 2010;163(5):709-16.
26. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223-30.
27. Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura ESL, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease. Pituitary. 2010;13(2):123-9.
28. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29-38. (Pubitemid 46041751)
29. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356(1):39-46. (Pubitemid 46041752)
30. Delgado V, Biermasz NR, van Thiel SW, Ewe SH, Ajmone Marsan N, Holman ER, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012;77:99-105.
31. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157-98. (Pubitemid 29362641)
32. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91(11):4482-8. (Pubitemid 44833427)
33. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152(4):645-54. (Pubitemid 40575811)
34. Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther. 2005;78(1):69-80. (Pubitemid 40956933)
35. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707-16. (Pubitemid 34552506)
36. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol. 2005;289(2):E278-87.
37. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115-22.
38. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012;366(10):914-24.
39. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med. 2010;362(19):1846-8.
40. Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, et al. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34-41.
41. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008;93(4):1412-7. (Pubitemid 351522738)
42. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol. 1989;120(6):760-6. (Pubitemid 19148444)
43. Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J, et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol. 1994;130(2):125-31. (Pubitemid 24112380)
44. Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology. 1982;110(4):1147-54.
45. de Bruin C, Feelders RA, Waaijers AM, van Koetsveld PM, Sprij-Mooij DM, Lamberts SW, et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol. 2009;42(1):47-56.
46. Xu Y, Berelowitz M, Bruno JF. Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology. 1995;136(11):5070-5.
47. Park S, Kamegai J, Kineman RD. Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: evidence for direct and somatostatin-mediated effects. Neuroendocrinology. 2003;78(3):163-75. (Pubitemid 37188082)
48. Feelders RA, De Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, et al. Medical treatment of Cushing's disease with pasireotide mono- or combination therapy with cabergoline and ketoconazole modulates somatostatin receptor subtype expression on corticotroph tumor cells. Endocrine Abstracts OR 146; 2010.
49. Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J Clin Endocrinol Metab. 1996;81(8):2885-90. (Pubitemid 26323880)
50. Dillard TH, Gultekin SH, Delashaw JB Jr, Yedinak CG, Neuwelt EA, Fleseriu M. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary. 2011;14(1):80-91.
51. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery. 2009;64(4):E773-4 (discussion E4).
52. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4592-9.
53. Curto L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, et al. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease - report of a case and literature review. Sci World J. 2010;10:2132-8.
54. McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Investig. 2011;41(10):1133-48.
55. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Investig. 2001;108(8):1123-31. (Pubitemid 32995370)
56. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology. 2006;147(9):4438-44. (Pubitemid 44268395)
57. Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, et al. Potential role for retinoic acid in patients with Cushing's disease. J Clin Endocrinol Metab. 2012;97(10):3577-83.
58. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Investig. 2011;121(12):4712-21.
59. Loli P, Berselli ME, Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. J Clin Endocrinol Metab. 1986;63(6):1365-71. (Pubitemid 17206431)
60. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987;317(13):812-8. (Pubitemid 17133360)
61. Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf). 1991;35(4):347-52.
62. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol. 2008;158(1):91-9. (Pubitemid 351211045)
63. Lamberts SW, Bons EG, Bruining HA, de Jong FH. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther. 1987;240(1):259-64. (Pubitemid 17235446)
64. Engelhardt D, Dorr G, Jaspers C, Knorr D. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klinische Wochenschrift. 1985;63(13):607-12. (Pubitemid 15039601)
65. Farwell AP, Devlin JT, Stewart JA. Total suppression of cortisol excretion by ketoconazole in the therapy of the ectopic adrenocorticotropic hormone syndrome. Am J Med. 1988;84(6):1063-6.
66. McCance DR, Hadden DR, Kennedy L, Sheridan B, Atkinson AB. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1987;27(5):593-9. (Pubitemid 17161172)
67. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994;330(4):263-72. (Pubitemid 24034139)
68. Nieman LK. Medical therapy of Cushing's disease. Pituitary. 2002;5(2):77-82. (Pubitemid 36336012)
69. Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology. 2010;92(Suppl 1):111-5.
70. Stalla GK, Stalla J, Huber M, Loeffler JP, Hollt V, von Werder K, et al. Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology. 1988;122(2):618-23. (Pubitemid 18060955)
71. Burrin JM, Yeo TH, Ashby MJ, Bloom SR. Effect of ketoconazole on adrenocorticotrophic hormone secretion in vitro and in vivo. J Endocrinol. 1986;108(1):37-41. (Pubitemid 16173323)
72. Terzolo M, Panarelli M, Piovesan A, Torta M, Paccotti P, Angeli A. Ketoconazole treatment in Cushing's disease. Effect on the circadian profile of plasma ACTH and cortisol. J Endocrinol Investig. 1988;11(10):717-21. (Pubitemid 19009044)
73. DeLeon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Crit Care Med. 2001;29(3):668-70. (Pubitemid 32225315)
74. Shibata S, Kami M, Kanda Y, Machida U, Iwata H, Kishi Y, et al. Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide. Am J Hematol. 2001;66(4):303-5. (Pubitemid 32210302)
75. Riedl M, Maier C, Zettinig G, Nowotny P, Schima W, Luger A. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol. 2006;154(4):519-24.
76. van der Pas R, Hofland LJ, Hofland J, Taylor AE, Arlt W, Steenbergen J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol. 2012;215(3):403-12.
77. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf). 1991;35(2):169-78.
78. Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev. 2011;7(6):323-35.
79. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27(27):4619-29.
80. Young RB, Bryson MJ, Sweat ML, Street JC. Complexing of DDT and o, p'DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem. 1973;4(6):585-91.
81. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Int Med. 1980;92(5):613-9. (Pubitemid 10107550)
82. Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2011;96(9):2796-804.
83. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D, et al. Treatment of Cushing's disease by O, p'DDD. Survey of 62 cases. N Engl J Med. 1979;300(9):459-64. (Pubitemid 9134790)
84. Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, et al. Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. Eur J Endocrinol. 2012;167(4):473-81.
85. Kawai S, Ichikawa Y, Kaburaki J, Yoshida T. 18 years mitotane therapy for intractable Cushing's disease. Lancet. 1999;354(9182):951. (Pubitemid 29424039)
86. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res. 2009;23(2):273-89.
87. Allolio B, Stuttmann R, Fischer H, Leonhard W, Winkelmann W. Long-term etomidate and adrenocortical suppression. Lancet. 1983;2(8350):626. (Pubitemid 13051068)
88. Fellows IW, Bastow MD, Byrne AJ, Allison SP. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed). 1983;287(6408):1835-7. (Pubitemid 14205219)
89. Schteingart DE. Drugs in the medical treatment of Cushing's syndrome. Expert Opin Emerg Drugs. 2009;14(4):661-71.
90. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab. 2001;86(9):4104-8. (Pubitemid 32848520)
91. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab. 1990;70(5):1426-30.
92. Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. Eur J Endocrinol. 2012;167(2):137-43.
93. Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, et al. Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11β-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study. Endocrine Abstracts OR012; 2012.
94. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009;160(6):1003-10.
95. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-49.
96. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal. 2007;19(11):2304-16. (Pubitemid 47361686)
97. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science (New York, NY). 2000;288(5463):154-7. (Pubitemid 30203051)
98. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6):2781-9.